Quantum BioPharma Ltd. (QNTM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Quantum BioPharma Ltd. (QNTM) trades at $3.44 with AI Score 45/100 (Grade C). Quantum BioPharma Ltd. is a biopharmaceutical company focused on researching and developing treatments for neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse. Market cap: $22.0M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026Analyst Coverage for QNTM: QNTM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QNTM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
QNTM: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Quantum BioPharma Ltd. (QNTM) Healthcare & Pipeline Overview
Quantum BioPharma Ltd. is a biopharmaceutical company developing biotech solutions for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. Their lead compound, Lucid-MS, is currently in Phase 2 clinical trials targeting myelin degradation in multiple sclerosis, positioning them within the specialty drug market.
What Is the Investment Thesis for QNTM?
Quantum BioPharma Ltd. presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. The company's primary value driver is the successful development and commercialization of Lucid-MS for multiple sclerosis, a market with significant unmet needs. Positive Phase 2 trial results would serve as a major catalyst, potentially leading to partnerships or acquisition. The company's treatment for alcohol misuse represents a secondary value driver. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $22.0M and a beta of 0.29, QNTM's stock is highly sensitive to news regarding its clinical programs.
Based on FMP financials and quantitative analysis
QNTM Key Highlights
Lead compound Lucid-MS is in Phase 2 clinical trials targeting multiple sclerosis.
- Developing a treatment for alcohol misuse for application in hospitals and other medical practices.
- Operates through two segments: Biopharmaceutical and Strategic Investments.
- Maintains a portfolio of strategic investments comprising loans secured by residential property.
- Formerly known as FSD Pharma Inc., changed its name to Quantum BioPharma Ltd. in August 2024.
Who Are QNTM's Competitors?
QNTM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QNTM's Key Strengths?
Lead compound in Phase 2 clinical trials.
- Focus on unmet medical needs in neurodegenerative diseases.
- Portfolio of strategic investments.
- Experienced management team.
What Are QNTM's Weaknesses?
Limited financial resources.
- Small number of employees.
- High reliance on the success of Lucid-MS.
- Early-stage development pipeline.
What Could Drive QNTM Stock Higher?
Announcement of Phase 2 clinical trial results for Lucid-MS.
- Continued development of treatment for alcohol misuse.
- Exploration of strategic partnerships and licensing agreements.
What Are the Key Risks for QNTM?
Financial-distress signal — its Altman Z-Score of -24.79 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of Lucid-MS in clinical trials.
- Delays in regulatory approval process.
- Competition from other pharmaceutical companies.
- Limited financial resources to support R&D activities.
What Are the Growth Opportunities for QNTM?
- Lucid-MS Clinical Trial Success: The successful completion of Phase 2 clinical trials for Lucid-MS and subsequent progression to Phase 3 represents a significant growth opportunity. Positive trial results could lead to accelerated regulatory approval and commercialization, capturing a share of the multi-billion dollar multiple sclerosis treatment market. The timeline for Phase 3 trials and potential market entry is estimated at 3-5 years, depending on regulatory pathways.
- Expansion into New Neurodegenerative Diseases: Quantum BioPharma can leverage its research and development capabilities to expand its pipeline into other neurodegenerative diseases, such as Alzheimer's and Parkinson's. These markets represent significant unmet needs and substantial commercial opportunities. This expansion would require additional investment in R&D and could take 5-7 years to yield marketable products.
- Strategic Partnerships and Licensing Agreements: Forming strategic partnerships with larger pharmaceutical companies for the development and commercialization of its drug candidates could provide Quantum BioPharma with access to additional funding, expertise, and distribution channels. Licensing agreements could generate upfront payments and royalties, providing a steady stream of revenue. These partnerships could materialize within the next 1-3 years.
- Development of Alcohol Misuse Treatment: The successful development and commercialization of its treatment for alcohol misuse represents another growth opportunity. This treatment could address a significant unmet need in hospitals and other medical settings. The timeline for regulatory approval and commercialization is estimated at 2-4 years.
- Geographic Expansion: Expanding its operations into new geographic markets, such as Europe and Asia, could provide Quantum BioPharma with access to a larger patient population and increased revenue opportunities. This expansion would require significant investment in infrastructure and regulatory compliance and could take 3-5 years to implement.
What Threats Does QNTM Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expirations.
What Are QNTM's Competitive Advantages?
- Patented new chemical entity (Lucid-MS) provides exclusivity.
- Focus on challenging neurodegenerative diseases creates a specialized niche.
- Strategic investments provide a diversified revenue stream.
- Proprietary research and development platform.
What Does QNTM Do?
Quantum BioPharma Ltd., formerly known as FSD Pharma Inc., is a biopharmaceutical company dedicated to the research and development of innovative treatments for challenging neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse disorders. Founded with the vision of addressing unmet medical needs in these therapeutic areas, the company operates through two segments: Biopharmaceutical and Strategic Investments. Quantum BioPharma's lead compound, Lucid-MS, a patented new chemical entity, is currently undergoing Phase 2 clinical trials to assess its efficacy in preventing and reversing myelin degradation, a key underlying mechanism in multiple sclerosis. Preclinical models have shown promising results. In addition to Lucid-MS, the company is also developing a treatment for alcohol misuse, intended for use in hospitals and other medical settings. Quantum BioPharma also maintains a portfolio of strategic investments comprising loans secured by residential property. The company changed its name to Quantum BioPharma Ltd. in August 2024 and is headquartered in Toronto, Canada.
What Products and Services Does QNTM Offer?
- Researches and develops biotech solutions for neurodegenerative disorders.
- Focuses on treatments for inflammatory and metabolic disorders.
- Develops treatments for alcohol misuse disorders.
- Operates through Biopharmaceutical and Strategic Investments segments.
- Lead compound Lucid-MS targets myelin degradation in multiple sclerosis.
- Maintains a portfolio of strategic investments comprising loans secured by residential property.
How Does QNTM Make Money?
- Develops and patents novel pharmaceutical compounds.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval from health authorities.
- Commercializes its approved drugs through partnerships or direct sales.
What Industry Does QNTM Operate In?
Quantum BioPharma Ltd. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, high regulatory scrutiny, and significant R&D costs. Companies like Quantum BioPharma focus on developing niche therapies for specific diseases. The market for multiple sclerosis treatments is substantial, driven by the increasing prevalence of the disease and the demand for more effective therapies. The company's success depends on its ability to navigate the complex regulatory landscape and successfully commercialize its drug candidates.
Who Are QNTM's Key Customers?
- Patients suffering from multiple sclerosis.
- Hospitals and medical practices treating alcohol misuse.
- Potential pharmaceutical partners for licensing and co-development agreements.
- Investors in strategic investments.
Company Profile
Quantum BioPharma Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Zeeshan Saeed. QNTM has traded publicly since 2018.
Financial Health
Quantum BioPharma Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.79 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -32.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.63 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -176.4%, the inverse of the P/E and a quick read on earnings relative to price.
QNTM Valuation & Market Position
With a $22.0M market cap, Quantum BioPharma Ltd. sits in the micro-cap segment of the market. Relative to its peer group, QNTM's quantitative score of 45/100 is below the peer average of 62/100.
Forward Outlook
Wall Street analysts project Quantum BioPharma Ltd. revenue of about $15.0M for fiscal 2026, with EPS near $-1.84.
QNTM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in upcoming growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to drug development.
- Market perception has improved due to recent partnerships that could enhance their research capabilities and market reach.
- Analysts have noted a growing interest in biopharma sectors, positioning Quantum BioPharma favorably within a booming industry.
Bear Case
- Concerns over the company's cash runway have surfaced, leading some investors to question sustainability without additional funding.
- Recent news about regulatory hurdles in the biopharma sector has created uncertainty around product timelines and approvals.
- Community discussions have highlighted skepticism regarding the scalability of their current projects, which may hinder growth potential.
- Some bearish views stem from broader market volatility, causing investors to be cautious about smaller biotech firms like Quantum BioPharma.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QNTM Latest News
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Jul 21, 2026
-
Earnings Scheduled For May 6, 2025
benzinga · May 6, 2025
QNTM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QNTM.
Price Targets
Wall Street price target analysis for QNTM.
QNTM MoonshotScore
What does this score mean?
The MoonshotScore rates QNTM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Zeeshan Saeed
Unknown
Zeeshan Saeed is the CEO of Quantum BioPharma Ltd. His background includes managing teams and overseeing the strategic direction of the company. Further details regarding his career history, education, and previous roles are not available.
Track Record: Zeeshan Saeed has overseen the company's transition to Quantum BioPharma Ltd. and the continued development of Lucid-MS. Specific achievements and milestones under his leadership are not available.
Common Questions About QNTM (Healthcare)
What does the AI Score mean for QNTM?
QNTM holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Quantum BioPharma Ltd. is a biopharmaceutical company focused on researching and developing treatments for neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse. Their lead …
What does Quantum BioPharma Ltd. do?
Quantum BioPharma Ltd. is a biopharmaceutical company focused on researching and developing treatments for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. Their lead compound, Lucid-MS, is in Phase 2 clinical trials for multiple sclerosis. The company also maintains a portfolio of strategic investments. QNTM aims to address unmet medical needs in these therapeutic areas through innovative drug development.
What do analysts say about QNTM stock?
Analyst coverage of Quantum BioPharma Ltd. (QNTM) is currently limited due to its small market capitalization and early-stage development pipeline. Key valuation metrics and growth considerations are heavily dependent on the success of Lucid-MS and other pipeline candidates. Investors should carefully consider the inherent risks associated with biopharmaceutical companies in early stages of clinical development. Further analyst insights are unavailable.
What are the main risks for QNTM?
Quantum BioPharma Ltd. faces significant risks inherent to the biopharmaceutical industry. These include the potential failure of Lucid-MS in clinical trials, delays in regulatory approval, and competition from established pharmaceutical companies with greater resources. The company's limited financial resources and small number of employees also pose challenges to its ability to execute its business plan. These factors could adversely affect the company's financial performance and stock price.
What are the key factors to evaluate for QNTM?
Quantum BioPharma Ltd. (QNTM) holds an AI score of 45/100 (low). presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. Not financial advice.
How frequently does QNTM data refresh on this page?
QNTM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven QNTM's recent stock price performance?
Quantum BioPharma Ltd. (QNTM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead compound in Phase 2 clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QNTM overvalued or undervalued right now?
Quantum BioPharma Ltd. (QNTM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research QNTM before investing?
Before investing in Quantum BioPharma Ltd. (QNTM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is an early-stage biopharmaceutical company with significant risks.